Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies

References

• CoiffierBAltmanAPuiCHYounesACairoMSGuidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based reviewJ Clin Oncol2008262767277818509186
   PubMed Web of Science ®Google Scholar
• HochbergJCairoMSTumor lysis syndrome: current perspectiveHaematologica20089391318166779
   PubMed Web of Science ®Google Scholar
• CairoMSBishopMTumour lysis syndrome: new therapeutic strategies and classificationBr J Haematol200412731115384972
   PubMed Web of Science ®Google Scholar
• HandeKRGarrowGCAcute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphomaAm J Med1993941331398430709
   PubMed Web of Science ®Google Scholar
• WossmannWSchrappeMMeyerUZimmermannMReiterAIncidence of tumor lysis syndrome in children with advanced stage Brukitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidaseAnn Hematol20038216016512634948
   PubMed Web of Science ®Google Scholar
• OdaMSattaYTakenakaOTakahataNLoss of urate oxidase activity in hominoids and its evolutionary implicationsMol Biol Evol20021964065311961098
   PubMed Web of Science ®Google Scholar
• GoldmanSLynchJHarrisonLPreliminary results of the addition of rasburicase to the reduction cycle and rituximab to the induction and consolidation cycles of FAB group C chemotherapy in children and adolescents with advanced stage (bone marrow ± CNS) mature B-cell non-Hodgkin lymphoma (B-NHL): a Children’s Oncology Group reportBlood2009114104
   Web of Science ®Google Scholar
• CairoMSCoiffierBReiterAYounesARecommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensusBr J Haematol201014957858620331465
   PubMed Web of Science ®Google Scholar
• Ten HarkelADJKist-van HoltheJEvan WeelMvan der VorstMMJAlkalinization and the tumor lysis syndromeMed Pediatr Oncol19983127289607427
   PubMedGoogle Scholar
• ChantadaGLSackmann-MurielFAlkalinization and tumor lysis syndromeMed Pediatr Oncol1999321569950210
   PubMedGoogle Scholar
• Van den BergHReintsemaAMRenal tubular damage in rasburicase: risks of alkalinisationAnn Oncol20041517517614679140
   PubMed Web of Science ®Google Scholar
• DeContiRCCalabresiPUse of allopurinol for prevention and control of hyperuricemia in patients with neoplastic diseaseN Engl J Med19662744814865904287
   PubMed Web of Science ®Google Scholar
• KrakoffIHMeyerRLPrevention of hyperuricemia in leukemia and lymphoma: use of allopurinol, a xanthine oxidase inhibitorJAMA19651931614297704
   PubMed Web of Science ®Google Scholar
• SmalleyRVGuaspariAHaase-StatzSAndersonSACederbergDHohnekerJAAllopurinol: intravenous use for prevention and treatment of hyperuricemiaJ Clin Oncol2000181758176310764437
   PubMed Web of Science ®Google Scholar
• Allopurinol [prescribing information]Corona, CAWatson Laboratories, Inc2006
   Google Scholar
• Uloric [prescribing information]Deerfield, ILTakeda Pharmaceuticals US2009
   Google Scholar
• Elitek [prescribing information]Bridgewater, NJsanofi-aventis US2010
   Google Scholar
• Data on file. Bridgewater, NJ: sanofi-aventis US.
   Google Scholar
• Fasturtec [summary of product characteristics]London, UKEuropean Medicines Agency2008
   Google Scholar
• GoldmanSCHolcenbergJSFinklesteinJZA randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysisBlood2001972998300311342423
   PubMed Web of Science ®Google Scholar
• PuiCHMahmoudHHWileyJMRecombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphomaJ Clin Oncol20011969770411157020
   PubMed Web of Science ®Google Scholar
• CoiffierBMounierNBolognaSEfficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) studyJ Clin Oncol2003214402440614581437
   PubMed Web of Science ®Google Scholar
• JehaSKantarjianHIrwinDEfficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trialLeukemia200519343815510203
   PubMed Web of Science ®Google Scholar
• LiuCYSims-McCallumRPSchifferCAA single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapyLeuk Res20052946346515725482
   PubMed Web of Science ®Google Scholar
• HoVQWetzsteinGAPattersonSGBradburyRAbbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndromeSupport Cancer Ther2006317818218632493
   PubMedGoogle Scholar
• HunterHMRuleSAJRasburicase is effective in the prophylaxis of tumour lysis syndrome when used over a short duration in patients with haematological malignancyBr J Haematol2005129Suppl 142
   Google Scholar
• WangLYShihLYChangHRecombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignanciesActa Haematol2006115353816424647
   PubMed Web of Science ®Google Scholar
• ArnoldTMReuterJPDelmanBSShanholtzCBUse of single-dose rasburicase in an obese femaleAnn Pharmacother2004381428143115292497
   PubMed Web of Science ®Google Scholar
• McDonnellAMLenzKLFrei-LahrDAHayslipJHallPDSingle-dose rasburicase 6 mg in the management of tumor lysis syndrome in adultsPharmacotherapy20062680681216716134
   PubMed Web of Science ®Google Scholar
• HutchersonDAGammonDCBhattMSFaneufMReduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancyPharmacotherapy20062624224716466328
   PubMed Web of Science ®Google Scholar
• ReevesDJBestulDJEvaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancerPharmacotherapy20082868569018503395
   PubMed Web of Science ®Google Scholar
• TrifilioSGordonLSinghalSReduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemiaBone Marrow Transplant200637997100116708061
   PubMed Web of Science ®Google Scholar
• LeeACLiCHSoKTChanRTreatment of impending tumor lysis with single-dose rasburicaseAnn Pharmacother2003371614161714565793
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services2009 Average Sales Price Drug Pricing Files. Available from: http://www.cms.hhs.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesPrice/downloads/April_2009_ASP_Pricing_File_by_HCPCS.zip. Accessed Mar 23 2009.
   Google Scholar
• BellTCandrilliSIrishWMorrisEGoldmanSCCairoMSAcute renal failure (ARF) with or without dialysis (D) is associated with a significant increase in mean length of stay (LOS) and total costs (TC) in patients hospitalized with acute leukemia (AL) and/or lymphoma (L)Proc Am Soc Clin Oncol200322 (Abstr 2195).
   Google Scholar